The price of IO Biotech Inc. (NASDAQ:IOBT) shares last traded on Wall Street rose 3.15% to $2.62.
Based on available information, 5 analysts follow IO Biotech Inc. (NASDAQ:IOBT). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $10.00, we find $15.00. Given the previous closing price of $2.54, this indicates a potential upside of 490.55 percent. IOBT stock price is now -2.64% away from the 50-day moving average and -35.40% away from the 200-day moving average. The market capitalization of the company currently stands at $83.87M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Among analysts, 0 rate the stock a hold while 5 rate it a buy. Brokers who have rated the stock have averaged $15.00 as their price target over the next twelve months.
.
A total of 11.14% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IOBT stock. A new stake in IO Biotech Inc. shares was purchased by NEWTYN MANAGEMENT, LLC during the first quarter worth $262,000. VICTORY CAPITAL MANAGEMENT INC invested $115,000 in shares of IOBT during the first quarter. In the first quarter, PSAGOT VALUE HOLDINGS LTD. / (ISRAEL) acquired a new stake in IO Biotech Inc. valued at approximately $107,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in IOBT for approximately $48,000. ANCORA ADVISORS, LLC purchased a new stake in IOBT valued at around $2,000 in the second quarter. In total, there are 22 active investors with 82.70% ownership of the company’s stock.
A candlestick chart of IO Biotech Inc. (NASDAQ: IOBT) showed a price of $2.4100 on Thursday morning. During the past 12 months, IO Biotech Inc. has had a low of $2.15 and a high of $9.77. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 25.00, and a quick ratio of 25.00. The fifty day moving average price for IOBT is $2.6910 and a two-hundred day moving average price translates $4.0560 for the stock.
The latest earnings results from IO Biotech Inc. (NASDAQ: IOBT) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.64, beating analysts’ expectations of -$0.68 by 0.04. This compares to -$25.18 EPS in the same period last year. The company reported revenue of $15.87 million for the quarter, compared to $7.04 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 125.29 percent.
IO Biotech Inc.(IOBT) Company Profile
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
